CDP: state-controlled drugmaker with modest upside, low conviction given liquidity and earnings-quality flags
Intrinsic value VND 13,564 vs market VND 12,100 — implied upside 12.1% (model confidence: low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược phẩm Trung ương Codupha (CDP) is a UPCOM-listed pharmaceutical manufacturer and distributor operating in the Vietnamese healthcare/consumer sector, classified under ICB 3 'Dược phẩm'. The firm reported revenue of VND 3,285.3 bn in 2025 and has notable scale in the domestic generics/OTC market. Ownership is concentrated: Tổng Công ty Dược Việt Nam (a state-owned pharmaceutical conglomerate) holds 66.35%, followed by institutional financial shareholders (DSC 14.87%, NTP AM 8.25%). CDP trades with effectively zero foreign room (foreign_room 0.0) and low average turnover (avg_volume_2w 1,124 shares), reflecting limited free float and liquidity on UPCOM.
Luận điểm đầu tư
CDP's valuation implies modest upside: the blended model yields an intrinsic value of VND 13,564 per share vs the match price of VND 12,100, a 12.1% gap. On fundamentals, the company shows improvement in profitability: net profit increased from VND 9.3 bn in 2023 to VND 35.4 bn in 2025, and ROE is 15.9% with an EPS of approximately VND 1,944. The dividend yield is meaningful at 7.4%, consistent with the SOE legacy of steady cash distributions.
Offsetting these positives are structural and execution risks. Reported margins remain thin (gross margin 6.6%, EBIT margin 1.75%, net margin 1.08%), and ROA is only 1.6%. Leverage metrics look elevated on a reported basis (Debt/Equity 9.6x) which, combined with net debt of roughly VND 961.5 bn, constrains balance-sheet flexibility. The model flags low earnings quality and illiquidity; trading liquidity and zero foreign room raise the effective investable free float and exit risk for institutional buyers. Finally, our model confidence is low, reducing conviction in the 12.1% implied upside.
Diễn giải định giá
Blend of a 10-year FCF DCF (70%) and a PE-based terminal valuation (30%), calibrated by isotonic mapping to peer outcomes.
- DCF inputs: base FCF VND 48,702,739,538 and WACC 10%; terminal growth 4%; TV accounts for 57.07% of enterprise value.
- PE inputs: fair PE 17.69 with a PE cap of 25; standalone PE intrinsic from the model is VND 34,386.3 per share before blending.
- Blend weights: 70% DCF / 30% PE produces the blended intrinsic VND 13,564 per share.
- Balance-sheet and cash: model net debt ~VND 961.5 bn reduces enterprise value to equity value.
- Sanity flags: illiquid stock, illiquid_upside_capped and low_earnings_quality lower model confidence to 'low'.
The blended intrinsic value implies a 12.1% upside but model confidence is low due to illiquidity and earnings-quality flags; the DCF leg produced an anomalous negative 'dcf_intrinsic' (-6,443.4) while the PE leg produced a much higher raw intrinsic (VND 34,386.3), hence the heavy reliance on blend calibration. Treat the VND 13,564 target as a probabilistic reference rather than a high-confidence fair value.
Các luận điểm cần cân nhắc
- Improving profitability: net profit rose from VND 9.3 bn (2023) to VND 35.4 bn (2025), supporting an EPS ~VND 1,944 and ROE 15.9%.
- Attractive cash return: dividend yield of 7.4% provides current-income support to returns even if capital appreciation is muted.
- Reasonable valuation on multiples: P/E 6.2x and P/B 0.97x suggest limited downside from current levels if operations remain stable.
- Liquidity and marketability: average 2-week volume only 1,124 shares and zero foreign room increase execution risk and may cap rerating despite intrinsic upside.
- Low earnings quality and model sanity flags increase the probability of earnings volatility or one-off items that could reverse recent profit growth (earnings_quality 27.4).
- High reported leverage (Debt/Equity 9.6x) and substantial net debt (~VND 961.5 bn) constrain reinvestment and make the company sensitive to working-capital swings.
- Concentrated SOE ownership (66.35%) limits free-float catalysts and could prioritize stakeholder objectives (e.g., employment, supply security) over margin expansion.
Bối cảnh ngành
The Vietnamese pharmaceutical subsector is fragmented, with many local generics players and a handful of larger SOE-related producers/distributors. SBV credit growth quotas and banking funding conditions can affect working-capital financing for mid-sized pharma firms; banks may also hold VAMC exposure that impacts sector lending. VAS accounting and government procurement practices can cause timing differences between reported revenue and cash. Peers show a wide dispersion in implied upside (sector median upside ~12.0%), indicating heterogeneous business models and valuation multiples across the subsector. For UPCom-listed names, low liquidity and limited foreign participation are common and often compress valuation multiples relative to HNX/HOSE peers.
Yếu tố rủi ro
- Illiquidity: avg_volume_2w 1,124 shares and UPCOM listing make entry/exit costly and can amplify short-term price moves.
- Earnings quality: earnings_quality score 27.4 and model sanity flag 'low_earnings_quality' suggest reliance on non-recurring items or accounting timing effects.
- High leverage: Debt/Equity 9.6x and net debt ~VND 961.5 bn increase refinancing and cash-flow risk if margins weaken.
- Concentrated ownership: state parent holds 66.35%, limiting free float and potential for minority-friendly corporate actions; also exposes the company to SOE policy objectives.
- Zero foreign room: foreign_room 0.0 prevents incremental demand from foreign investors and narrows buyer base.
- Regulatory and procurement risk: price controls, tender competition in public hospitals, and differences under VAS accounting could pressure margins.
Yếu tố có thể tác động
- Sustained margin expansion and recurring profit growth reported over consecutive quarters that improves earnings-quality perception.
- Corporate actions that increase free float or open foreign ownership (e.g., share re-allocation or divestment by state parent).
- Material debt reduction or conversion that reduces Debt/Equity from current reported 9.6x and the net-debt burden (~VND 961.5 bn).
- Improved liquidity or inclusion on a higher-profile trading venue that reduces the illiquidity discount.
Đánh giá dấu hiệu kế toán
No Beneish M-Score is provided and explicit mscore fields are null. However, the model raised 'low_earnings_quality' as a sanity flag and the earnings_quality metric is 27.4 (relatively low), which is the principal forensic concern. There are no explicit red flags in the forensic.summary, but low earnings-quality combined with atypical model outputs (negative dcf_intrinsic vs very high pe_intrinsic) warrants caution and further forensic review of one-off items, related-party transactions, and working-capital accounting.
Lịch sử định giá
Model track record: 9 years with a hit rate of 62.5% for directional calls (years where >10% upside matched next-year direction). Historical average upside on successful calls is high (avg_upside_pct 131.1%), but sample size is limited and past performance does not guarantee future accuracy. Given the model's 'low' confidence for this stock, historical hit rate provides only partial comfort.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.